Royal Bank of Canada »

Inhibrx Biosciences shares owned by Royal Bank of Canada

Quarter-by-quarter ownership of Inhibrx Biosciences (INBX) shares owned by Royal Bank of Canada from 13F filings

Historical chart of Royal Bank of Canada investment in Inhibrx Biosciences

Tip: Access up to 7 years of quarterly data

All positions including Inhibrx Biosciences held by Royal Bank of Canada consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Inhibrx Biosciences by Royal Bank of Canada

Quarter filed Position value Share count Share price at filing
2024-09-30 $27k 1.9k 14.37
2024-06-30 $11k 1.1k 10.42

More positions owned by Royal Bank of Canada

Spdr S&p 500 Etf Tr Tr Unit (SPY)
Microsoft Corporation (MSFT)
Apple (AAPL)
NVIDIA Corporation (NVDA)
Amazon (AMZN)
Toronto Dominion Bk Ont Com New (TD)
Rbc Cad (RY)
Invesco Qqq Tr Unit Ser 1 (QQQ)
Ishares Tr Core S&p500 Etf (IVV)
Bk Nova Cad (BNS)
Ishares Tr Russell 2000 Etf (IWM)
Bank Of Montreal Cadcom (BMO)
JPMorgan Chase & Co. (JPM)
Enbridge (ENB)
Cibc Cad (CM)

View all positions for Royal Bank of Canada

Top funds holding Inhibrx Biosciences

Viking Global Investors
Perceptive Advisors
BlackRock
BlackRock
Sofinnova Ventures
Vanguard Group
Slotnik Capital
Geode Capital Management
Morgan Stanley
Caption Management
Kennedy Capital Management
Arrowpoint Asset Management
Susquehanna International
State Street Corporation
Schonfeld Strategic Advisors

View all funds holding Inhibrx Biosciences